Research programme: oncobiotic therapeutics - Evelo Biosciences

Drug Profile

Research programme: oncobiotic therapeutics - Evelo Biosciences

Alternative Names: EDP 1503; Immuno-microbiome Cancer therapies - Evelo Biosciences; Microbiome-based immuno-oncology therapeutics - Evelo Biosciences; Monoclonal microbial -- Evelo Biosciences; Onco-microbials - Evelo Biosciences

Latest Information Update: 04 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Chicago
  • Developer Evelo Biosciences
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Immunomodulators; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Malignant melanoma; Renal cell carcinoma

Most Recent Events

  • 23 Jul 2018 Evelo Biosciences and Merck plans a phase II trial (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy, Second-line therapy of greater, Metastatic disease) for Melanoma in USA (NCT03595683)
  • 31 May 2018 US FDA accepts IND application to initiate phase IIa trial in Melanoma
  • 29 May 2018 Evelo Biosciences plans a first-in-human clinical trial for Malignant melanoma (Metastatic disease, Combination therapy, First-line therapy, Second-line therapy or greater) in USA in H2-2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top